Companies › Neurotronic
2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Jan 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Neurotronic Catheter | – | Phase 1 | Diabetes Mellitus, Type 2 | Jan 2029 |
| Single Arm non-Randomized Ablation Treatment | – | Phase 1 | Diabetes Mellitus, Type 2 | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05369065 | Single Arm non-Randomized Ablation Treatment | Phase 1 | Diabetes Mellitus, Type 2 | Cardiovascular | Jan 2029 |
| NCT05363761 | Neurotronic Catheter | Phase 1 | Diabetes Mellitus, Type 2 | Cardiovascular | Jan 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.